- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07809425
External Oblique Intercostal Block With or Without Intravenous Lidocaine Infusion for Analgesia in Patients Undergoing Gastric Bypass Surgery
September 2, 2026 updated by: Nevine Mostafa Soliman, Menoufia University
External Oblique Intercostal Block With or Without Intravenous Lidocaine Infusion for Analgesia in Patients Undergoing Gastric Bypass Surgery: a Randomized Controlled Trial
Adding a perioperative lidocaine infusion (1.5 mg/kg loading + 1.5 mg/kg/h) to bilateral EOIB and low dose fentanyl loading reduces intraoperative fentanyl consumption (ANI guided rescue) compared to placebo, without increasing adverse events.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
- Drug: We hypothesize that adding a perioperative lidocaine infusion (1.5 mg/kg loading + 1.5 mg/kg/h) to bilateral EOIB and low dose fentanyl loading reduces intraoperative fentanyl consumption.
- Other: Bilateral EOIB + fentanyl 1 μg/kg loading + normal saline loading (equivalent volume) + normal saline infusion (equivalent rate).
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nevine Mostafa Soliman
- Phone Number: +201128861471
- Email: mostafanevine@gmail.com
Study Locations
-
-
-
Alexandria, Egypt
- Recruiting
- faculty of Medicine
-
Contact:
- Nevine Mostafa Soliman
- Phone Number: +201128861471
- Email: mostafanevine@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 18-60 years.
- BMI ≥ 35 kg/m².
- ASA physical status II or III.
- Scheduled for elective laparoscopic Roux en Y gastric bypass.
- Ability to provide written informed consent.
Exclusion Criteria:
- Refusal.
- Allergy or contraindication to lidocaine, fentanyl, ropivacaine, or any study medication.
- Chronic opioid use or dependence.
- Significant hepatic (AST/ALT> 3× normal, cirrhosis) or renal impairment (CrCl< 30 mL/min).
- Second or third degree AV block or significant bradyarrhythmia without pacemaker.
- Coagulopathy, anticoagulation incompatible with regional anesthesia, or infection at block site.
- Pregnancy or lactation.
- Severe psychiatric or cognitive disorder.
- Failed bilateral EOIB (absence of sensory loss in T6-T10 after 30 min) - excluded from analysis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group L (lidocaine)
Bilateral EOIB + fentanyl 1 μg/kg loading + lidocaine 1.5 mg/kg loading + lidocaine infusion 1.5 mg/kg/h.
|
Adding a perioperative lidocaine infusion (1.5 mg/kg loading + 1.5 mg/kg/h) to bilateral EOIB and low dose fentanyl loading reduces intraoperative fentanyl consumption (ANI guided rescue) compared to placebo, without increasing adverse events.
|
|
Placebo Comparator: Group P (placebo)
Bilateral EOIB + fentanyl 1 μg/kg loading + normal saline loading (equivalent volume) + normal saline infusion (equivalent rate).
|
Bilateral EOIB + fentanyl 1 μg/kg loading + normal saline loading (equivalent volume) + normal saline infusion (equivalent rate).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total intraoperative fentanyl consumption
Time Frame: Intraoperative time, during surgery
|
Total intraoperative fentanyl consumption (μg) = loading dose (1 μg/kg) + rescue boluses.
|
Intraoperative time, during surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative morphine consumption
Time Frame: The first 24 hours
|
Postoperative morphine consumption (mg) at 24 hours.
|
The first 24 hours
|
|
First rescue fentanyl and time to first postoperative morphine
Time Frame: The first 24 hours
|
Time to first rescue fentanyl (from induction to first bolus) and Time to first postoperative morphine (from PACU arrival to first dose).
|
The first 24 hours
|
|
Pain scores
Time Frame: Upon arrival, 1 hour, 2 hours, 6 hours, 12 hours, 24 hours.
|
Pain scores (VAS score ranging 0-100) at Post Anesthetic Care Unit arrival, 1 hour, 2 hours, 6 hours, 12 hours, 24 hours.
|
Upon arrival, 1 hour, 2 hours, 6 hours, 12 hours, 24 hours.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 15, 2026
Primary Completion (Estimated)
January 15, 2027
Study Completion (Estimated)
February 1, 2027
Study Registration Dates
First Submitted
August 30, 2026
First Submitted That Met QC Criteria
September 2, 2026
First Posted (Actual)
September 9, 2026
Study Record Updates
Last Update Posted (Actual)
September 9, 2026
Last Update Submitted That Met QC Criteria
September 2, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8/2026ANET3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.